Sign In
Buy SUPN
$44.63
-0.98 (-2.15%)
At Close: Jul 31, 2026
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Dimensional Fund Advisors LP
03:39am, Wednesday, 29'th Jul 2026
Dimensional Fund Advisors LP lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 14.9% during the first quarter, according to its most recent disclosure with the Securitie
Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: Should You Buy?
11:06am, Tuesday, 28'th Jul 2026
Supernus (SUPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Supernus (SUPN) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Monday, 27'th Jul 2026
Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
05:05pm, Wednesday, 22'nd Jul 2026
ROCKVILLE, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
08:30am, Tuesday, 14'th Jul 2026
ROCKVILLE, Md., July 14, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?
10:25am, Thursday, 09'th Jul 2026
Supernus (SUPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Supernus Pharmaceuticals to Participate in June Investor Conferences
04:30pm, Wednesday, 27'th May 2026
ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
01:10am, Wednesday, 13'th May 2026
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year
12:50pm, Tuesday, 12'th May 2026
Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide.
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
05:00pm, Wednesday, 06'th May 2026
ROCKVILLE, Md. , May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
05:00pm, Wednesday, 06'th May 2026
ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
10:21pm, Tuesday, 05'th May 2026
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
08:01pm, Tuesday, 05'th May 2026
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates
07:10pm, Tuesday, 05'th May 2026
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.42 per share a year ago.
Supernus Announces First Quarter 2026 Financial Results
04:05pm, Tuesday, 05'th May 2026
ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent
